Investigating the impact of CircRNAs on cancer progression and drug resistance

The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance.

High Response Rates in Psoriasis With Oral IL-23 Inhibitor

An oral interleukin (IL)-23 inhibitor for psoriasis produced 16-week response rates as high as 79% in moderate-to-severe plaque psoriasis, a prospective phase II trial showed.

February 8, 2024

Visa V stock analysis and Why I think V stock will sell off.

August 22, 2023

iOnctura raises nearly $86m in Series B to fund Phase II cancer trials

Syncona was the major investor in iOnctura having invested €30m ($32.2m) for a 23% stake in the company. Image Credit: eamesBot / Shutterstock. Swiss biopharma

June 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.